Lymfoom geassocieerde studies
Open studies
| Naam | ZUMA-2 cohort 3 |
| Titel | A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) |
| Status | Open in AUMC (AMC), EMC & UMCG |
| Medicatie | KTE-X19 |
| Populatie | r/r MCL BTKi-naive (i.e. Ibrutinib, Acalabrutinib) |
| Documenten | Subject eligibility |
| Naam | EPCORE DLBCL-1 |
| Titel | A randomized phase 3 trial of subcutaneous epcoritamab versus investigator choice chemotherapy (R-Gem/Ox or R-benda) in relapsed/ refractory DLBCL |
| Status | Open |
| Informatie |
rr DLBCL (de novo or tFL); HGBCL (de novo or tFL); FL grade 3b. |
| Deelnemers |
Open at Erasmus MC (p.lugtenburg@erasmusmc.nl) |
| Documenten | Eligibility checklist |
| Naam | Mangrove studie (Beigene-3111-306) |
| Titel | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation |
| Status | Open |
| Deelnemers |
Erasmus MC Rotterdam – J Doorduijn |
| Documenten | In- en exclusiecriteria |
| Naam | HD21 |
| Titel | Treatment optimization trial in the first line treatment of adv stage HL: comparison of 4-6 cycles of esc BEACOPP with 4-6 cycles of BrECADD |
| Status | Open |
| Deelnemers | AmsterdamUMC - VUmc - JM Zijlstra MeanderMC – JC Regelink Jeroen Bosch ziekenhuis- H Pruijt ADR ziekenhuis Goes- S Kuipers OLVG A’dam – A. Gerrits WFG Hoorn- C Klerk Haga ziekenhuis- L Bohmer LUMC- H Veelken Anthonius ziekenhuis- M Sohne |
| Documenten | Flow + in- en exclusiecriteria Protocol |